From OCC tweetpost:
Drug access news: Beginning August 26, 2019, patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who meet eligibility criteria will have access to Lynparza (a PARP inhibitor) free of charge for a maximum of 24 months or until disease progression on treatment in their FIRST line of treatment through the expansion of the AstraZeneca & Merck Oncology Patient Support Program.
Patients should receive Lynparza no later than 8 weeks after completion of platinum-based chemotherapy. This Program will run for 12 months (from August 26, 2019 – August 26, 2020, inclusive) or until public drug plan listing in the patient’s province, whichever comes first. To learn more about whether you may be eligible and to enroll in the Program please speak with your oncologist.
It looks like you might be new to OVdialogue. Please register or sign in to participate in discussions.